$IMVT News

Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30

Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43

HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $40

Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial

Immunovant Q4 Earnings Call Highlights

Immunovant Stock Surges Despite Disappointing Earnings Miss

Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT)

Immunovant Inc (NASDAQ:IMVT) Surges 26% Pre-Market on Strong IMVT-1402 Clinical Data Despite Wider Q4 Loss

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate

Immunovant: Best-In-Class Ambitions, Still Unproven

Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $32

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow